Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05111626




Registration number
NCT05111626
Ethics application status
Date submitted
29/10/2021
Date registered
8/11/2021
Date last updated
30/05/2024

Titles & IDs
Public title
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer
Scientific title
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression
Secondary ID [1] 0 0
2023-505458-16
Secondary ID [2] 0 0
20210098
Universal Trial Number (UTN)
Trial acronym
FORTITUDE-102
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Gastric Cancer 0 0
Gastroesophageal Junction Adenocarcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Stomach
Cancer 0 0 0 0
Oesophageal (gullet)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Bemarituzumab
Treatment: Drugs - Nivolumab
Treatment: Drugs - Chemotherapy
Other interventions - Placebo

Experimental: Part 1 Safety Lead-in: Bemarituzumab with mFOLFOX6 and Nivolumab - Participants will be administered bemarituzumab at different doses with mFOLFOX6 and nivolumab to determine the recommended phase 3 dose (RP3D) based on occurrence of dose-limiting toxicities (DLTs), and on an evaluation of the overall safety, tolerability, and pharmacokinetics (PK).

Experimental: Part 2: Bemarituzumab with chemotherapy (mFOLFOX6 or CAPOX) and Nivolumab - Participants will be administered bemarituzumab at the RP3D determined from Part 1 in combination with mFOLFOX6 and nivolumab on a 14-day cycle.
Or participants will be administered bemarituzumab in combination with CAPOX and nivolumab on a 21-day cycle.

Placebo Comparator: Part 2: Placebo with chemotherapy (mFOLFOX6 or CAPOX) and Nivolumab - Participants will be administered placebo comparator in combination with mFOLFOX6 and nivolumab on a 14-day cycle.
Or participants will be administered placebo comparator in combination with CAPOX and nivolumab on a 21-day cycle.


Treatment: Drugs: Bemarituzumab
Bemarituzumab will be administered as intravenous (IV) infusion.

Treatment: Drugs: Nivolumab
Nivolumab will be administered as IV infusion.

Treatment: Drugs: Chemotherapy
mFOLFOX6: 5-fluorouracil, leucovorin, and oxaliplatin will be administered as IV infusion.
OR CAPOX: oxaliplatin will be administered as IV infusion and capecitabine will be administered orally.

Other interventions: Placebo
Placebo will be administered as IV infusion.
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Part 1: Number of Participants Who Experienced DLTs
Timepoint [1] 0 0
28 days
Primary outcome [2] 0 0
Part 1: Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAEs)
Timepoint [2] 0 0
Up to 4.5 years
Primary outcome [3] 0 0
Part 1: Number of Participants Who Experienced One or More Related TEAEs
Timepoint [3] 0 0
Up to 4.5 years
Primary outcome [4] 0 0
Part 1: Number of Participants With Clinically Significant Changes in Vital Signs
Timepoint [4] 0 0
Up to 4.5 years
Primary outcome [5] 0 0
Part 1: Number of Participants With Clinically Significant Changes in Visual Acuity
Timepoint [5] 0 0
Up to 4.5 years
Primary outcome [6] 0 0
Part 1: Number of Participants With Clinically Significant Changes in Physical Examinations
Timepoint [6] 0 0
Up to 4.5 years
Primary outcome [7] 0 0
Part 1: Number of Participants with Clinically Significant Changes in Clinical Laboratory Tests
Timepoint [7] 0 0
Up to 4.5 years
Primary outcome [8] 0 0
Part 2: Overall Survival in FGFR2b = 10% 2+/3+ Tumor Cell Staining Participants
Timepoint [8] 0 0
Up to 4.5 years
Secondary outcome [1] 0 0
Part 1: Objective Response (OR)
Timepoint [1] 0 0
Up to 4.5 years
Secondary outcome [2] 0 0
Part 1: Duration of Response (DoR)
Timepoint [2] 0 0
Up to 4.5 years
Secondary outcome [3] 0 0
Part 1: Disease Control Rate (DCR)
Timepoint [3] 0 0
Up to 4.5 years
Secondary outcome [4] 0 0
Part 1: Progression Free Survival (PFS)
Timepoint [4] 0 0
Up to 4.5 years
Secondary outcome [5] 0 0
Part 1: Overall Survival
Timepoint [5] 0 0
Up to 4.5 years
Secondary outcome [6] 0 0
Part 1: Maximum Observed Concentration (Cmax) of Bemarituzumab
Timepoint [6] 0 0
Day 1 to up to 4.5 years
Secondary outcome [7] 0 0
Part 1: Area Under the Concentration Time Curve (AUC) of Bemarituzumab
Timepoint [7] 0 0
Day 1 to up to 4.5 years
Secondary outcome [8] 0 0
Part 1: Observed Concentration at the End of a Dose Interval (Ctrough) of Bemarituzumab
Timepoint [8] 0 0
Day 1 to up to 4.5 years
Secondary outcome [9] 0 0
Part 1: Number of Participants With Anti-Bemarituzumab Antibody Formation
Timepoint [9] 0 0
Day 1 to up to 4.5 years
Secondary outcome [10] 0 0
Part 2: PFS in FGFR2b = 10% 2+/3+ Tumor Cell Staining Participants
Timepoint [10] 0 0
Up to 4.5 years
Secondary outcome [11] 0 0
Part 2: OR in FGFR2b = 10% 2+/3+ Tumor Cell Staining Participants
Timepoint [11] 0 0
Up to 4.5 years
Secondary outcome [12] 0 0
Part 2: Number of Participants Who Experienced One or More TEAEs
Timepoint [12] 0 0
Up to 4.5 years
Secondary outcome [13] 0 0
Part 2: Number of Participants With Clinically Significant Changes in Vital Signs
Timepoint [13] 0 0
Up to 4.5 years
Secondary outcome [14] 0 0
Part 2: Number of Participants With Clinically Significant Changes in Visual Acuity
Timepoint [14] 0 0
Up to 4.5 years
Secondary outcome [15] 0 0
Part 2: Number of Participants with Clinically Significant Changes in Clinical Laboratory Tests
Timepoint [15] 0 0
Up to 4.5 years
Secondary outcome [16] 0 0
Part 2: Overall Survival in All Randomized Participants
Timepoint [16] 0 0
Up to 4.5 years
Secondary outcome [17] 0 0
Part 2: PFS in All Randomized Participants
Timepoint [17] 0 0
Up to 4.5 years
Secondary outcome [18] 0 0
Part 2: Objective Response Rate (ORR) in All Randomized Participants
Timepoint [18] 0 0
Up to 4.5 years
Secondary outcome [19] 0 0
Part 2: DoR in FGFR2b = 10% 2+/3+ Tumor Cell Staining Participants
Timepoint [19] 0 0
Up to 4.5 years
Secondary outcome [20] 0 0
Part 2: DCR in FGFR2b = 10% 2+/3+ Tumor Cell Staining Participants
Timepoint [20] 0 0
Up to 4.5 years
Secondary outcome [21] 0 0
Part 2: Mean Score in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Version 3.0 (QLQ-C30) Individual Scores in FGFR2b = 10% 2+/3+ Tumor Cell Staining Participants
Timepoint [21] 0 0
Up to 4.5 years
Secondary outcome [22] 0 0
Part 2: Change From Baseline in EORTC QLQ-C30 Individual Scores in FGFR2b = 10% 2+/3+ Tumor Cell Staining Participants
Timepoint [22] 0 0
Baseline to up to 4.5 years
Secondary outcome [23] 0 0
Part 2: Mean Score in Stomach Cancer Related Symptoms Measured by EORTC Quality of Life Questionnaire-Stomach 22 (QLQ-STO22) in FGFR2b = 10% 2+/3+ Tumor Cell Staining Participants
Timepoint [23] 0 0
Up to 4.5 years
Secondary outcome [24] 0 0
Part 2: Change From Baseline in Stomach Cancer Related Symptoms Measured by EORTC QLQ-STO22 in FGFR2b = 10% 2+/3+ Tumor Cell Staining Participants
Timepoint [24] 0 0
Baseline to up to 4.5 years
Secondary outcome [25] 0 0
Part 2: Mean Score of Visual Analogue Scale (VAS) Scores as Measured by EuroQol 5-dimensional (EQ-5D-5L) in FGFR2b = 10% 2+/3+ Tumor Cell Staining Participants
Timepoint [25] 0 0
Up to 4.5 years
Secondary outcome [26] 0 0
Part 2: Change From Baseline of VAS Scores as Measured by EQ-5D-5L in FGFR2b = 10% 2+/3+ Tumor Cell Staining Participants
Timepoint [26] 0 0
Baseline to up to 4.5 years
Secondary outcome [27] 0 0
Part 2: Time to Deterioration in Stomach Cancer Related Symptoms Measured by EORTC QLQ-STO22 in FGFR2b = 10% 2+/3+ Tumor Cell Staining Participants
Timepoint [27] 0 0
Day 1 to up to 4.5 years
Secondary outcome [28] 0 0
Part 2: Time to Deterioration in Health-Related Quality of Life (HRQoL) Scores in FGFR2b = 10% 2+/3+ Tumor Cell Staining Participants
Timepoint [28] 0 0
Day 1 to up to 4.5 years
Secondary outcome [29] 0 0
Part 2: Time to Deterioration in Physical Function Scores in FGFR2b = 10% 2+/3+ Tumor Cell Staining Participants
Timepoint [29] 0 0
Day 1 to up to 4.5 years
Secondary outcome [30] 0 0
Part 2: Cmax of Bemarituzumab
Timepoint [30] 0 0
Day 1 to up to 4.5 years
Secondary outcome [31] 0 0
Part 2: Ctrough of Bemarituzumab
Timepoint [31] 0 0
Day 1 to up to 4.5 years
Secondary outcome [32] 0 0
Part 2: Number of Participants With Anti-Bemarituzumab Antibody Formation
Timepoint [32] 0 0
Day 1 to up to 4.5 years

Eligibility
Key inclusion criteria
Inclusion Criteria Part 1 and Part 2:

- Adult with unresectable, locally advanced or metastatic (not amenable to curative
therapy) histologically documented gastric or gastroesophageal junction adenocarcinoma

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

- Measurable disease or non-measurable, but evaluable disease, according to Response
Evaluation Criteria in Solid Tumours version 1.1 (RECIST v1.1)

- Participant has no contraindications to nivolumab and either mFOLFOX6 or CAPOX
chemotherapy as per local prescribing information. Participants in Part 1 must have no
contraindications to mFOLFOX6. Participants in Part 2 with contraindications to
mFOLFOX6 are permitted and may be administered the CAPOX regimen, if no
contraindications for this regimen exist. Participants in Part 2 with
contraindications to CAPOX are permitted and may be administered the mFOLFOX6 regimen,
if no contraindications for this regimen exist

- Adequate organ function as follows:

- Absolute neutrophil count = 1.5 x 10^9/L

- Platelet count = 100 x 10^9/L

- Hemoglobin = 9 g/dL without red blood cell (RBC) transfusion within 7 days prior
to the first dose of study treatment

- Aspartate aminotransaminase (AST) and Alanine aminotransaminase (ALT) <3 x upper
limit of normal (ULN) (or < 5 x ULN if liver involvement)

- Total bilirubin <1.5 x ULN (or < 2 x ULN if liver involvement or Gilbert's
disease)

- Part 1 only: Calculated or measured creatinine clearance (CrCl) of = 50 mL/minute
calculated using the formula of Cockcroft and Gault ([140 - Age] × Mass [kg]/[72
× Creatinine mg/dL]) (x 0.85 if female).

- Part 2 only: Calculated or measured creatinine clearance (CrCl) of = 30 mL/minute
calculated using the formula of Cockcroft and Gault ([140 - Age] × Mass [kg]/[72 ×
Creatinine mg/dL]) (x 0.85 if female).

- INR or prothrombin time (PT) < 1.5 × ULN except for participants receiving
anticoagulation, who must be on a stable dose of anticoagulant therapy for 6 weeks
prior to enrollment

Additional Inclusion Criteria Part 2:

- No prior treatment for metastatic or unresectable disease except for a maximum of

1 dose of chemotherapy with or without nivolumab; prior adjuvant, neo-adjuvant, and
peri-operative therapy is allowed, provided it has been completed more than 6 months
prior to the first dose of study treatment

- Fibroblast growth factor receptor 2b (FGFR2b) = 10% 2+/3+ tumor cells (TC) as
determined by centrally performed immunohistochemistry (IHC) testing, based on tumor
sample either archival (obtained within 6 months/180 days prior to signing
pre-screening informed consent) or a fresh biopsy.
Minimum age
18 Years
Maximum age
100 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Prior treatment with any selective inhibitor of the fibroblast growth factor
(FGF)-FGFR pathway

- Known positive human epidermal growth factor receptor 2 (HER2) status

- Untreated or symptomatic central nervous system disease metastases and leptomeningeal
disease

- Peripheral sensory neuropathy grade 2 or higher

- Clinically significant cardiac disease

- Other malignancy within the last 2 years (exceptions for definitively treated disease)

- Chronic or systemic ophthalmologic disorders

- Major surgery or other investigational study within 28 days prior to randomization

- Palliative radiotherapy within 14 days prior to randomization

- Abnormalities of the cornea that may pose an increased risk of developing a corneal
ulcer

- Active autoimmune disease that has required systemic treatment (except replacement
therapy) within the past 2 years or any other diseases requiring immunosuppressive
therapy while on study

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/03/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
26/09/2026
Actual
Sample size
Target
528
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
GenesisCare -North Shore Oncology - St Leonards
Recruitment hospital [2] 0 0
Calvary Mater Newcastle Hospital - Waratah
Recruitment hospital [3] 0 0
The Queen Elizabeth Hospital - Woodville South
Recruitment hospital [4] 0 0
Ballarat Health Services - Ballarat
Recruitment hospital [5] 0 0
Austin Health, Austin Hospital - Heidelberg
Recruitment postcode(s) [1] 0 0
2065 - St Leonards
Recruitment postcode(s) [2] 0 0
2298 - Waratah
Recruitment postcode(s) [3] 0 0
5011 - Woodville South
Recruitment postcode(s) [4] 0 0
3350 - Ballarat
Recruitment postcode(s) [5] 0 0
3084 - Heidelberg
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Minnesota
Country [9] 0 0
United States of America
State/province [9] 0 0
New Jersey
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
North Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Oregon
Country [14] 0 0
United States of America
State/province [14] 0 0
Pennsylvania
Country [15] 0 0
United States of America
State/province [15] 0 0
South Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Virginia
Country [19] 0 0
United States of America
State/province [19] 0 0
Washington
Country [20] 0 0
United States of America
State/province [20] 0 0
Wisconsin
Country [21] 0 0
Argentina
State/province [21] 0 0
Buenos Aires
Country [22] 0 0
Argentina
State/province [22] 0 0
Distrito Federal
Country [23] 0 0
Argentina
State/province [23] 0 0
Jujuy
Country [24] 0 0
Argentina
State/province [24] 0 0
Río Negro
Country [25] 0 0
Argentina
State/province [25] 0 0
Tucuman
Country [26] 0 0
Argentina
State/province [26] 0 0
Capital Federal
Country [27] 0 0
Argentina
State/province [27] 0 0
Córdoba
Country [28] 0 0
Argentina
State/province [28] 0 0
La Rioja
Country [29] 0 0
Austria
State/province [29] 0 0
Graz
Country [30] 0 0
Austria
State/province [30] 0 0
Innsbruck
Country [31] 0 0
Austria
State/province [31] 0 0
Rankweil
Country [32] 0 0
Austria
State/province [32] 0 0
Salzburg
Country [33] 0 0
Austria
State/province [33] 0 0
Wiener Neustadt
Country [34] 0 0
Austria
State/province [34] 0 0
Wien
Country [35] 0 0
Belgium
State/province [35] 0 0
Bruxelles
Country [36] 0 0
Belgium
State/province [36] 0 0
Charleroi
Country [37] 0 0
Belgium
State/province [37] 0 0
Edegem
Country [38] 0 0
Belgium
State/province [38] 0 0
Gent
Country [39] 0 0
Belgium
State/province [39] 0 0
Jette
Country [40] 0 0
Belgium
State/province [40] 0 0
Leuven
Country [41] 0 0
Belgium
State/province [41] 0 0
Libramont
Country [42] 0 0
Belgium
State/province [42] 0 0
Liege
Country [43] 0 0
Belgium
State/province [43] 0 0
Turnhout
Country [44] 0 0
Brazil
State/province [44] 0 0
Ceará
Country [45] 0 0
Brazil
State/province [45] 0 0
Distrito Federal
Country [46] 0 0
Brazil
State/province [46] 0 0
Espírito Santo
Country [47] 0 0
Brazil
State/province [47] 0 0
Minas Gerais
Country [48] 0 0
Brazil
State/province [48] 0 0
Rio Grande Do Norte
Country [49] 0 0
Brazil
State/province [49] 0 0
Rio Grande Do Sul
Country [50] 0 0
Brazil
State/province [50] 0 0
São Paulo
Country [51] 0 0
Brazil
State/province [51] 0 0
Rio de Janeiro
Country [52] 0 0
Bulgaria
State/province [52] 0 0
Burgas
Country [53] 0 0
Bulgaria
State/province [53] 0 0
Haskovo
Country [54] 0 0
Bulgaria
State/province [54] 0 0
Panagyurishte
Country [55] 0 0
Bulgaria
State/province [55] 0 0
Plovdiv
Country [56] 0 0
Bulgaria
State/province [56] 0 0
Sofia
Country [57] 0 0
Canada
State/province [57] 0 0
Ontario
Country [58] 0 0
Canada
State/province [58] 0 0
Quebec
Country [59] 0 0
Chile
State/province [59] 0 0
Santiago
Country [60] 0 0
Chile
State/province [60] 0 0
Valparaíso
Country [61] 0 0
Chile
State/province [61] 0 0
La Serena
Country [62] 0 0
China
State/province [62] 0 0
Beijing
Country [63] 0 0
China
State/province [63] 0 0
Chongqing
Country [64] 0 0
China
State/province [64] 0 0
Fujian
Country [65] 0 0
China
State/province [65] 0 0
Gansu
Country [66] 0 0
China
State/province [66] 0 0
Guangdong
Country [67] 0 0
China
State/province [67] 0 0
Guangxi
Country [68] 0 0
China
State/province [68] 0 0
Hainan
Country [69] 0 0
China
State/province [69] 0 0
Hebei
Country [70] 0 0
China
State/province [70] 0 0
Heilongjiang
Country [71] 0 0
China
State/province [71] 0 0
Henan
Country [72] 0 0
China
State/province [72] 0 0
Hubei
Country [73] 0 0
China
State/province [73] 0 0
Hunan
Country [74] 0 0
China
State/province [74] 0 0
Inner Mongolia
Country [75] 0 0
China
State/province [75] 0 0
Jiangsu
Country [76] 0 0
China
State/province [76] 0 0
Jiangxi
Country [77] 0 0
China
State/province [77] 0 0
Ningxia
Country [78] 0 0
China
State/province [78] 0 0
Shaanxi
Country [79] 0 0
China
State/province [79] 0 0
Shandong
Country [80] 0 0
China
State/province [80] 0 0
Shanghai
Country [81] 0 0
China
State/province [81] 0 0
Shanxi
Country [82] 0 0
China
State/province [82] 0 0
Sichuan
Country [83] 0 0
China
State/province [83] 0 0
Yunnan
Country [84] 0 0
China
State/province [84] 0 0
Zhejiang
Country [85] 0 0
Czechia
State/province [85] 0 0
Hradec Kralove
Country [86] 0 0
Czechia
State/province [86] 0 0
Olomouc
Country [87] 0 0
Czechia
State/province [87] 0 0
Praha 10
Country [88] 0 0
Czechia
State/province [88] 0 0
Praha 2
Country [89] 0 0
Czechia
State/province [89] 0 0
Praha 4
Country [90] 0 0
France
State/province [90] 0 0
Amiens Cedex 1
Country [91] 0 0
France
State/province [91] 0 0
Besançon
Country [92] 0 0
France
State/province [92] 0 0
Bordeaux
Country [93] 0 0
France
State/province [93] 0 0
Brest
Country [94] 0 0
France
State/province [94] 0 0
Clermont-Ferrand cedex 1
Country [95] 0 0
France
State/province [95] 0 0
Lille
Country [96] 0 0
France
State/province [96] 0 0
Limoges Cedex
Country [97] 0 0
France
State/province [97] 0 0
Lyon cedex 8
Country [98] 0 0
France
State/province [98] 0 0
Nice
Country [99] 0 0
France
State/province [99] 0 0
Paris Cedex 10
Country [100] 0 0
France
State/province [100] 0 0
Paris Cedex 14
Country [101] 0 0
France
State/province [101] 0 0
Paris
Country [102] 0 0
France
State/province [102] 0 0
Rouen Cedex
Country [103] 0 0
France
State/province [103] 0 0
Saint Herblain
Country [104] 0 0
France
State/province [104] 0 0
Saint Priest en Jarez
Country [105] 0 0
France
State/province [105] 0 0
Strasbourg cedex
Country [106] 0 0
France
State/province [106] 0 0
Toulouse Cedex 9
Country [107] 0 0
France
State/province [107] 0 0
Villejuif
Country [108] 0 0
Germany
State/province [108] 0 0
Berlin
Country [109] 0 0
Germany
State/province [109] 0 0
Dresden
Country [110] 0 0
Germany
State/province [110] 0 0
Frankfurt am Main
Country [111] 0 0
Germany
State/province [111] 0 0
Hamburg
Country [112] 0 0
Germany
State/province [112] 0 0
Hannover
Country [113] 0 0
Germany
State/province [113] 0 0
Kiel
Country [114] 0 0
Germany
State/province [114] 0 0
Leipzig
Country [115] 0 0
Germany
State/province [115] 0 0
Ludwigsburg
Country [116] 0 0
Germany
State/province [116] 0 0
Mainz
Country [117] 0 0
Germany
State/province [117] 0 0
Mannheim
Country [118] 0 0
Germany
State/province [118] 0 0
Muenchen
Country [119] 0 0
Germany
State/province [119] 0 0
Tuebingen
Country [120] 0 0
Germany
State/province [120] 0 0
Ulm
Country [121] 0 0
Germany
State/province [121] 0 0
Wolfsburg
Country [122] 0 0
Hong Kong
State/province [122] 0 0
Shatin, New Territories
Country [123] 0 0
Hungary
State/province [123] 0 0
Budapest
Country [124] 0 0
Hungary
State/province [124] 0 0
Debrecen
Country [125] 0 0
Hungary
State/province [125] 0 0
Nyiregyhaza
Country [126] 0 0
Hungary
State/province [126] 0 0
Szekszard
Country [127] 0 0
Hungary
State/province [127] 0 0
Szolnok
Country [128] 0 0
Hungary
State/province [128] 0 0
Tatabanya
Country [129] 0 0
Israel
State/province [129] 0 0
Haifa
Country [130] 0 0
Israel
State/province [130] 0 0
Jerusalem
Country [131] 0 0
Israel
State/province [131] 0 0
Ramat Gan
Country [132] 0 0
Israel
State/province [132] 0 0
Tel Aviv
Country [133] 0 0
Italy
State/province [133] 0 0
Ancona
Country [134] 0 0
Italy
State/province [134] 0 0
Bergamo
Country [135] 0 0
Italy
State/province [135] 0 0
Castellana Grotte
Country [136] 0 0
Italy
State/province [136] 0 0
Cremona
Country [137] 0 0
Italy
State/province [137] 0 0
Firenze
Country [138] 0 0
Italy
State/province [138] 0 0
Genova
Country [139] 0 0
Italy
State/province [139] 0 0
Milano
Country [140] 0 0
Italy
State/province [140] 0 0
Napoli
Country [141] 0 0
Italy
State/province [141] 0 0
Padova
Country [142] 0 0
Italy
State/province [142] 0 0
Pisa
Country [143] 0 0
Japan
State/province [143] 0 0
Aichi
Country [144] 0 0
Japan
State/province [144] 0 0
Chiba
Country [145] 0 0
Japan
State/province [145] 0 0
Ehime
Country [146] 0 0
Japan
State/province [146] 0 0
Fukuoka
Country [147] 0 0
Japan
State/province [147] 0 0
Gifu
Country [148] 0 0
Japan
State/province [148] 0 0
Hokkaido
Country [149] 0 0
Japan
State/province [149] 0 0
Hyogo
Country [150] 0 0
Japan
State/province [150] 0 0
Kanagawa
Country [151] 0 0
Japan
State/province [151] 0 0
Niigata
Country [152] 0 0
Japan
State/province [152] 0 0
Osaka
Country [153] 0 0
Japan
State/province [153] 0 0
Saitama
Country [154] 0 0
Japan
State/province [154] 0 0
Shizuoka
Country [155] 0 0
Japan
State/province [155] 0 0
Tokyo
Country [156] 0 0
Korea, Republic of
State/province [156] 0 0
Daegu
Country [157] 0 0
Korea, Republic of
State/province [157] 0 0
Daejeon
Country [158] 0 0
Korea, Republic of
State/province [158] 0 0
Goyang-si Gyeonggi-do
Country [159] 0 0
Korea, Republic of
State/province [159] 0 0
Jeonju-si, Jeollabuk-do
Country [160] 0 0
Korea, Republic of
State/province [160] 0 0
Seongnam-si, Gyeonggi-do
Country [161] 0 0
Korea, Republic of
State/province [161] 0 0
Seoul
Country [162] 0 0
Poland
State/province [162] 0 0
Bielsko-Biala
Country [163] 0 0
Poland
State/province [163] 0 0
Gliwice
Country [164] 0 0
Poland
State/province [164] 0 0
Konin
Country [165] 0 0
Poland
State/province [165] 0 0
Lublin
Country [166] 0 0
Poland
State/province [166] 0 0
Olsztyn
Country [167] 0 0
Poland
State/province [167] 0 0
Siedlce
Country [168] 0 0
Poland
State/province [168] 0 0
Skorzewo
Country [169] 0 0
Poland
State/province [169] 0 0
Szczecin
Country [170] 0 0
Poland
State/province [170] 0 0
Warszawa
Country [171] 0 0
Poland
State/province [171] 0 0
Wroclaw
Country [172] 0 0
Portugal
State/province [172] 0 0
Braga
Country [173] 0 0
Portugal
State/province [173] 0 0
Guimaraes
Country [174] 0 0
Portugal
State/province [174] 0 0
Lisboa
Country [175] 0 0
Portugal
State/province [175] 0 0
Matosinhos
Country [176] 0 0
Portugal
State/province [176] 0 0
Porto
Country [177] 0 0
Romania
State/province [177] 0 0
Bucharest
Country [178] 0 0
Romania
State/province [178] 0 0
Cluj Napoca
Country [179] 0 0
Romania
State/province [179] 0 0
Cluj-Napoca
Country [180] 0 0
Romania
State/province [180] 0 0
Craiova
Country [181] 0 0
Romania
State/province [181] 0 0
Iasi
Country [182] 0 0
Romania
State/province [182] 0 0
Timisoara
Country [183] 0 0
Singapore
State/province [183] 0 0
Singapore
Country [184] 0 0
Spain
State/province [184] 0 0
Andalucía
Country [185] 0 0
Spain
State/province [185] 0 0
Asturias
Country [186] 0 0
Spain
State/province [186] 0 0
Cantabria
Country [187] 0 0
Spain
State/province [187] 0 0
Cataluña
Country [188] 0 0
Spain
State/province [188] 0 0
Comunidad Valenciana
Country [189] 0 0
Spain
State/province [189] 0 0
Galicia
Country [190] 0 0
Spain
State/province [190] 0 0
Navarra
Country [191] 0 0
Spain
State/province [191] 0 0
Madrid
Country [192] 0 0
Switzerland
State/province [192] 0 0
Basel
Country [193] 0 0
Switzerland
State/province [193] 0 0
Bern
Country [194] 0 0
Switzerland
State/province [194] 0 0
Chur
Country [195] 0 0
Switzerland
State/province [195] 0 0
Geneve
Country [196] 0 0
Switzerland
State/province [196] 0 0
Zurich
Country [197] 0 0
Taiwan
State/province [197] 0 0
Kaohsiung
Country [198] 0 0
Taiwan
State/province [198] 0 0
Taichung
Country [199] 0 0
Taiwan
State/province [199] 0 0
Tainan
Country [200] 0 0
Taiwan
State/province [200] 0 0
Taipei
Country [201] 0 0
Thailand
State/province [201] 0 0
Bangkok
Country [202] 0 0
Thailand
State/province [202] 0 0
Chiang Mai
Country [203] 0 0
Thailand
State/province [203] 0 0
Chiang Rai
Country [204] 0 0
Thailand
State/province [204] 0 0
Songkhla
Country [205] 0 0
United Kingdom
State/province [205] 0 0
Cambridge
Country [206] 0 0
United Kingdom
State/province [206] 0 0
Coventry
Country [207] 0 0
United Kingdom
State/province [207] 0 0
Dundee
Country [208] 0 0
United Kingdom
State/province [208] 0 0
London
Country [209] 0 0
United Kingdom
State/province [209] 0 0
Manchester
Country [210] 0 0
United Kingdom
State/province [210] 0 0
Northwood
Country [211] 0 0
United Kingdom
State/province [211] 0 0
Torquay

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Amgen
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus
5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) and nivolumab.

The main objective Part 2 is to compare efficacy of bemarituzumab plus chemotherapy (mFOLFOX6
or capecitabine combined with oxaliplatin (CAPOX)) and nivolumab to placebo plus chemotherapy
(mFOLFOX6 or CAPOX) and nivolumab as assessed by overall survival.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05111626
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
MD
Address 0 0
Amgen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Amgen Call Center
Address 0 0
Country 0 0
Phone 0 0
866-572-6436
Fax 0 0
Email 0 0
medinfo@amgen.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05111626